アステラス製薬
The U.S. Food and Drug Administration (FDA) granted the application for enfortumab vedotin-ejfv accelerated approval, priority review designation, and breakthrough therapy designation. The FDA granted the approval of Padcev to Astellas Pharma US Inc.